News articles about Midatech Pharma (NASDAQ:MTP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Midatech Pharma earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.1171477249026 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Midatech Pharma (MTP) traded up $0.01 during mid-day trading on Monday, reaching $0.98. 4,600 shares of the company traded hands, compared to its average volume of 12,504. Midatech Pharma has a 1 year low of $0.92 and a 1 year high of $3.65. The company has a quick ratio of 1.49, a current ratio of 1.62 and a debt-to-equity ratio of 0.03.

ILLEGAL ACTIVITY WARNING: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at

Midatech Pharma Company Profile

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Insider Buying and Selling by Quarter for Midatech Pharma (NASDAQ:MTP)

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.